Pharma BD Deal Intelligence
Sanofi-Aventis acquired Fovea Pharmaceuticals, a French ophthalmology-focused biotech, for a total enterprise value of up to EUR 370 million (~$540 million), comprising an upfront payment and milestone payments tied to Fovea's three clinical compounds. Announced October 1, 2009 and closed October 30, 2009, the acquisition laid the foundation of an ophthalmology franchise for Sanofi-Aventis as it faced generic pressure on Plavix. Fovea's venture backers, including Sofinnova Partners, Abingworth, the Wellcome Trust and Gimv, exited through the sale.